LEGN.US

The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday it recorded net sales of approximately $72 million in the first quarter for its Carvykti cancer drug.

Looking up: Legend’s first-quarter sales for Carvykti were up 30.9% from $55 million in last year’s fourth quarter.

Take Note: Legend Biotech is commercializing Carvykti with Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ.US), in an agreement that requires Legend to share 50% of overseas sales of the drug with Janssen.

Digging Deeper: Carvykti is the first CAR-T cell therapy developed by a Chinese company, and gained global reach through a 2017 partnership between Legend and Janssen. Before the drug’s approval, Legend had been spending heavily on R&D, which weighed on Genscript’s profits. Following the product’s approval by the U.S. Food and Drug Administration (FDA), it has accumulated net sales of $206 million in the year since its launch.

Market Reaction: Legend Biotech fell 4.6% to $52.24 in New York on Tuesday, but still trades near its 52-week high. Genscript closed up 5% at HK$21 by the midday break in Hong Kong on Wednesday. The stock now trades in the middle of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Illustration of Hong Kong as a ipo pipeline and crypto lab for China

Hong Kong: China’s IPO pipeline and crypto lab

Companies raised $13.6 billion through Hong Kong IPOs in the first half of the year, giving the city the global fundraising title for that period. What's behind the sudden boom? And a growing number of Chinese companies are experimenting with cryptocurrencies in Hong Kong, even as such currencies are banned on the Mainland. What's driving such different approaches on the Mainland and in Hong Kong?